Coherus BioSciences, Inc.: directors' dealings · United States · SEC (Form 4)

About Coherus BioSciences, Inc.

Coherus BioSciences, Inc. is a U.S.-listed biopharmaceutical company trading on the Nasdaq under the ticker CHRS, headquartered in Redwood City, California, United States. Over 2025, the company executed a major strategic reset and rebranded to Coherus Oncology, signaling a decisive shift away from its legacy biosimilar footprint toward a focused oncology platform built around commercial assets, clinical development, and business development partnerships. That repositioning is central to the investment case: Coherus is no longer primarily a biosimilar story, but a smaller oncology-focused biotech/commercial hybrid with pipeline optionality. ([investors.coherus.com](https://investors.coherus.com/news-releases/news-release-details/coherus-completes-strategic-transformation-coherus-oncology/)) Historically, Coherus built its business around UDENYCA, a biosimilar to Neulasta (pegfilgrastim), and later added LOQTORZI, a next-generation PD-1 inhibitor. Following the divestiture of the UDENYCA franchise to Intas, management stated that the company would concentrate on the research, development, commercialization, and strategic partnering of innovative cancer immunotherapies. As of the latest company update, Coherus describes itself as a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline of two mid-stage clinical candidates. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1512762/000155837025005835/chrs-20241231xars.pdf)) The company’s commercial strategy is anchored in LOQTORZI, which is being promoted in relapsed/metastatic nasopharyngeal carcinoma, while the pipeline is designed to broaden the addressable oncology opportunity. Tagmokitug is a highly selective anti-CCR8 cytolytic antibody in Phase 1b/2a studies across multiple solid tumors, and casdozokitug is a novel IL-27 antagonistic antibody being studied in Phase 2 first-line hepatocellular carcinoma. Coherus has also indicated that it intends to pursue ex-U.S. licensing deals as clinical data matures, which suggests a capital-efficient monetization strategy rather than a broad, fully self-funded global buildout. ([investors.coherus.com](https://investors.coherus.com/news-releases/news-release-details/coherus-oncology-reports-first-quarter-2026-financial-results/)) Coherus was founded in 2010 and went public in November 2014. Its evolution is notable: the company started as a biosimilar developer and then used that commercial base to pivot into immuno-oncology. This history matters for investors because it explains both the revenue base and the strategic complexity of the recent transition. The firm remains relatively small versus large oncology incumbents and must compete in a highly crowded market against larger pharmaceutical companies and specialized biotech peers with deeper capital resources and broader commercial infrastructure. Its differentiation therefore depends on clinical execution, regulatory progress, and the ability to show that its mechanisms of action can translate into meaningful patient benefit. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1512762/000155837025005835/chrs-20241231xars.pdf)) Recent developments have been material. In 2025, Coherus completed its strategic transformation to an oncology-only company, repurchased roughly $170 million of convertible notes, and later raised equity in 2026 to fund LOQTORZI commercialization and pipeline advancement. In the first quarter of 2026, net revenue increased year over year, driven largely by LOQTORZI volume growth, while cash and marketable securities remained solid. For investors, CHRS offers a high-risk, high-upside oncology narrative on the Nasdaq in the United States: improving commercial traction, a concentrated pipeline, and meaningful clinical readouts expected in 2026. ([investors.coherus.com](https://investors.coherus.com/news-releases/news-release-details/coherus-completes-strategic-transformation-coherus-oncology/))